Response to Comments: MolDX Pigmented Lesion Assay

This policy (A58073) is a response-to-comments notice regarding the MolDX: Pigmented Lesion Assay LCD and records administrative dates (comment period 5/30/2019–7/14/2019; notice period 4/23/2020–6/7/2020; effective 6/7/2020). The document does not contain specific clinical coverage criteria, limitations, frequency limits, or required claim documentation; review the referenced LCD (L38153/DL38153) for the actual coverage policy. Manual review is recommended to extract any substantive coverage rules from the underlying LCD.

"This document is a response-to-comments notice for the MolDX: Pigmented Lesion Assay LCD and provides administrative dates (comment period 2019-05-30 to 2019-07-14; notice period 2020-04-23 to 2020..."

Sign up to see full coverage criteria, indications, and limitations.